Eidos & biotechnology firm BridgeBio present data from phase 2 OLE
Category: #health  | By Nikita Chaurasia  | Date: 2019-11-18 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eidos & biotechnology firm BridgeBio present data from phase 2 OLE

 

  • Lower rates of cardiovascular hospitalizations and mortality were witnessed.
  • Echocardiographic parameters and cardiac biomarkers were stable in the Phase 2 OLE in patients with AG10.

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company and BridgeBio Pharma, Inc. (BridgeBio), lately came up with positive data with from the phase 2 clinical trial’s current Open Label Extension (OLE) of companies perusing AG10. The OLE study was inclined on addressing the unmet need in disease caused by TTR, amyloidosis cardiomyopathy (ATTR-CM). For the uninitiated, ATTR-CM is potentially lethal and underdiagnosed disease.

The update from Phase 2 OLE revealed AG10’s continued tolerability in patents with developed ATTR-CM, commented the President and Chief Medical Officer of Edios Jonathan Fox. The President further went on to state that lower rates of cardiovascular hospitalizations and mortality were witnessed as compared to the forlorn hope for ATTR-CM patients who were untreated with disease gravity of similar scale. Fox is buoyed by the promising data that has underpinned the growth of AG10 that is dubbed ‘best-in-class treatment’ given in stabilizes and binds TTR in the blood, thereby intercepting progression of the disease and warding off formation of amlyloid.

During the OLE since the start of phase 2, reportedly study participants were given 800mg of AG10 twice daily that were followed for a median of 65 weeks. Further, echocardiographic and cardiac biomarkers parameters were steady in the Phase 2 OLE in patients with AG10.

As the first registrational primary endpoint, modification in six-minute walk distance in 12 months will be assessed between placebo groups and active treatment. Besides, therapies’ concomitant use meant for ATTR-CM treatment may get the green signal. As it appears, enrollment of Part A is proclaimed to turn into reality in the later part of 2020, while top line data is anticipated in 2021. The phase 3 study is enrolling across six countries at 44 sites.
 

Source Credit: https://bridgebio.com/news/bridgebio-and-eidos-present-data-from-phase-2-open-label-extension-suggesting-long-term-tolerability-of-ag10-and-stabilization-of-transthyretin-amyloid-cardiomyopathy-disease-measures

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Samsung kickstarts chip production with 3nm process technology

Samsung kickstarts chip production with 3nm process technology

By Nikita Chaurasia

Samsung Electronics Co Ltd has reportedly declared that it has begun the mass production of chips using advanced 3-nanometre technology. The company is the first in the entire world to do so and is actively looking for new clients to contest with Tai...

Progcap nabs $40Mn in funding round for expansion & product development

Progcap nabs $40Mn in funding round for expansion & product development

By Nikita Chaurasia

Progcap, a pioneer in the field of corporate-driven financing solutions for small and medium-sized businesses (SMBs), has secured $40 million in private equity capital at $600 million valuation. The raised capital forms a part of the Series C exte...

Microsoft solidifies Qatar investment; Unveils new high-tech office

Microsoft solidifies Qatar investment; Unveils new high-tech office

By Nikita Chaurasia

Microsoft, the global tech behemoth, has recently stated that it is expanding its operation in Qatar by unveiling a new Lusail City unit, the firm’s largest and fourth in the country. This new facility forms part of a substantial investment tha...